We found that UM171, a clinical phase 2 drug for haematopoietic stem cell transplantation, structurally mimics the cancer-mutated loop and acts as a molecular glue for wild-type KBTBD4 and HDAC1/2, resolving the long-standing puzzle of UM171’s mechanism of action. The gene discussed is HDAC1; the disease is cancer.